AP NEWS

Pipeline Review for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - H1 2018 - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Adrenoleukodystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Companies Mentioned

Applied Genetic Technologies Corp bluebird bio Inc MedDay SA Minoryx Therapeutics sl SOM Biotech SL Viking Therapeutics Inc

Key Topics Covered

Introduction Report Coverage Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development Applied Genetic Technologies Corp bluebird bio Inc MedDay SA Minoryx Therapeutics sl SOM Biotech SL Viking Therapeutics Inc Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles biotin - Drug Profile Product Description Mechanism Of Action R&D Progress DRX-065 - Drug Profile Product Description Mechanism Of Action R&D Progress DUOC-01 - Drug Profile Product Description Mechanism Of Action R&D Progress elivaldogene tavalentivec - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile Product Description Mechanism Of Action R&D Progress MGTA-456 - Drug Profile Product Description Mechanism Of Action R&D Progress MIN-102 - Drug Profile Product Description Mechanism Of Action R&D Progress OP-101 - Drug Profile Product Description Mechanism Of Action R&D Progress pioglitazone hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress sobetirome - Drug Profile Product Description Mechanism Of Action R&D Progress SOM-1201 - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile Product Description Mechanism Of Action R&D Progress temsirolimus - Drug Profile Product Description Mechanism Of Action R&D Progress VK-0214 - Drug Profile Product Description Mechanism Of Action R&D Progress VK-2809 - Drug Profile Product Description Mechanism Of Action R&D Progress Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - Dormant Projects Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/nc6cmk/pipeline_review?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006302/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 11:39 AM/DISC: 06/05/2018 11:39 AM

http://www.businesswire.com/news/home/20180605006302/en

AP RADIO
Update hourly